How do I calculate peptide concentration after adding water?

Divide the amount in the vial by the volume of water you added. A 10 mg vial mixed with 2 mL gives 10 ÷ 2 = 5 mg/mL, which is the same as 5,000 mcg/mL.

How many units are in 1 mL on a U-100 syringe?

A U-100 insulin syringe is marked so that 100 units equal 1 mL. Each unit is 0.01 mL, so 0.25 mL reads as 25 units.

How do I convert mg to mcg?

Multiply milligrams by 1,000. 1 mg = 1,000 mcg, so 0.25 mg = 250 mcg. To go back, divide mcg by 1,000.

Can I convert units on the syringe back to an amount?

Yes. Divide the units by 100 to get mL, then multiply by the concentration. 20 units = 0.20 mL; at 5 mg/mL that holds 1 mg. The calculator does this when you type units into the units box.

Does adding more water change how much is in the vial?

No. The total in the vial stays the same. More water lowers the concentration, so the same amount takes up more volume and more units on the syringe.

Why is IU treated differently from mg?

IU measures biological activity, not weight, so there is no universal IU-to-mg rule. The calculator uses the IU count printed on your own vial label instead of guessing.

Does PeptideWhiz suggest doses?

No. PeptideWhiz never suggests or recommends an amount. Every number comes from you, and the tool only does the arithmetic. It is not medical advice.

Do I need an account to use the calculator?

No. The calculator is free and works without an account. An account only lets you save results to your stack and tracker.

Peptide Calculator

Vial and water math for Cagrilintide, with a research record of published human trials. Math only, no suggested amounts.

Free · no account needed

Compound (Optional)

Desired Amount Per Dose

units (U-100)

Vial Strength (Total mg of Your Vial)

Reconstitution Solution Added

Titration Schedule (Optional)

Results

Draw to

—units

Enter amount, vial and Reconstitution Solution

ConcentrationConc.

—mg/mL

Your dose

—mg

Doses / vial

—

More than 100 units (over 1 mL). This won't fit in a single U-100 syringe draw. Double-check your numbers or use more water / a smaller amount.

U-100 Syringe · 1 mL

Notes

PeptideWhizpeptidewhiz.app · research use only

Research use only (RUO). Results are math on the values you enter only, not a recommendation or prescription for human use. Not medical advice. Always verify your own measurements. Full disclaimer

About Cagrilintide

Cagrilintide is a long-acting analogue of amylin, a hormone released with insulin that affects fullness and stomach emptying. It is being studied alone and in a fixed combination with semaglutide, known in trials as CagriSema.

Research status

Cagrilintide is not approved by the FDA or any other regulator. Its human data come from phase 1 to phase 3 trials, including the REDEFINE program listed below.

How the math works for any vial (concentration, U-100 units, mg and mcg) is explained step by step on the main peptide reconstitution calculator page. Read the full What is Cagrilintide? guide for mechanism, trials and conditions researched.

What published studies used

Research record, not a recommendation or protocol

These are published human trials of Cagrilintide from the PeptideWhiz study library. The last column quotes each study’s PubMed abstract word for word, so it shows what that study reported giving its participants under medical supervision. It is not advice, and the calculator never fills these numbers in on its own: you can copy one only by tapping its button and confirming.

Study	Year	Journal	As reported in the abstract	PubMed
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.	2026	The lancet. Diabetes & endocrinology	“The primary endpoint was change in HbA1c from baseline to week 68 with cagrilintide-semaglutide (2·4 mg each) versus semaglutide 2·4 mg in the full analysis set; safety was assessed in all participants who received at least one dose of study product.”	PMID 42251859
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.	2026	Hypertension (Dallas, Tex. : 1979)	“The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.”	PMID 41328546
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.	2025	The New England journal of medicine	“Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.”	PMID 40544433
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.	2025	The New England journal of medicine	“In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeks.”	PMID 40544432
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.	2024	Diabetes, obesity & metabolism	“This was a double-blind study (NCT05804162) in which healthy participants were randomized to cagrilintide, administered as a once-weekly subcutaneous injection dose escalated to 4.5 mg, or a placebo.”	PMID 39279639

Disclaimer: this table is an educational research record. It does not recommend, suggest or endorse any amount, schedule or use, and it is not medical advice. Decisions about any medicine belong with a licensed clinician.

Cagrilintide calculator FAQ

What is Cagrilintide?

Cagrilintide is a investigational long-acting amylin analogue. Cagrilintide is a long-acting analogue of amylin, a hormone released with insulin that affects fullness and stomach emptying.

Is Cagrilintide approved?

Cagrilintide is not approved by the FDA or any other regulator. Its human data come from phase 1 to phase 3 trials, including the REDEFINE program listed below.

Does this page suggest a Cagrilintide dose?

No. The calculator dose field starts empty and PeptideWhiz never suggests, recommends or calculates an amount for anyone. The study table is a research record of what published trials reported, not a recommendation or protocol.

Where do the study numbers on this page come from?

Each row quotes the abstract of a published human trial (5 trials, 2024 to 2026) word for word, as indexed in PubMed, with a link to the PubMed record. Nothing is rounded, combined or converted.

How does the calculator work with a Cagrilintide vial?

Pick Cagrilintide in step 1 if you want it on your result card, then enter the vial amount printed on your own label and the water volume actually added. The tool divides one by the other for concentration and shows the matching U-100 syringe units for an amount you type. Pens and pre-filled syringes are already in liquid form and are not reconstituted.

Sources

Study rows: PubMed records linked in the table (abstracts checked against PubMed on October 31, 2026). Unit math: see the sources on the main calculator.

Reviewed by the PeptideWhiz team on October 31, 2026. For research and education only.